Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan

被引：0
|
作者：
Moon Jin Kim
Gyeong-Won Lee
Jong Woo Seo
Hyun-Jung Kim
Sung-Nam Lim
Cheolwon Suh
机构：
[1] Gyeongsang National University,Department of Internal Medicine, School of Medicine
[2] Gyeongsang Institute of Health Science,Division of Oncology, Department of Medicine, Asan Medical Center
[3] Gyeongnam Regional Cancer Center,Division of Hematology
[4] University of Ulsan College of Medicine,Oncology, Department of Internal Medicine, School of Medicine
[5] Gyeongsang National University,undefined
来源：
Investigational New Drugs | 2011年 / 29卷
关键词：
Interstitial pneumonitis; Radioimmunotherapy; Yttrium-90; Ibritumomab tiuxetan; Diffuse large B cell lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is no previous report of fatal interstitial pneumonitis related to the administration of yttirum-90 ibritumomab tiuxetan. We report first case of fatal interstitial pneumonitis in a 35-year-old female patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. A pathological evaluation through a surgical lung biopsy demonstrated a “interstitial pneumonitis” pattern. Although high-dose methylprednisolone was administered, she died due to acute respiratory distress syndrome, secondary to radioimmunotherapy-induced interstitial pneumonitis. In this report, we discuss the etiology, diagnosis, and management of radioimmunotherapy-induced interstitial pneumonitis.
引用
收藏
页码：1098 / 1101
页数：3
相关论文
共 50 条
  • [1] Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
    Kim, Moon Jin
    Lee, Gyeong-Won
    Seo, Jong Woo
    Kim, Hyun-Jung
    Lim, Sung-Nam
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1098 - 1101
  • [2] Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma
    Demeter, J.
    Balassa, K.
    Domotor, M.
    Egyed, M.
    Gasztonyi, Z.
    Aryab, H.
    Gurzo, M.
    Ivayi, J.
    Klucsik, Zs.
    Sreter, L.
    Nagy, Zs.
    BLOOD REVIEWS, 2007, 21 : S138 - S139
  • [3] The use of Yttrium-90 -: Ibritumomab Tiuxetan in follicular lymphoma
    Dolera, T. Mut
    Bello, P.
    Olivas, C.
    Vercher, J. L.
    Asensio, I.
    Gil, H.
    Rivas, A.
    Velasco, R. P.
    Ruiz, C.
    Marti, J. F.
    Mateo, A.
    La Fe, H. U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S263 - S263
  • [4] The use of Yttrium-90 - Ibritumomab tiuxetan in follicular lymphoma
    Kolindou, A.
    Kitsou, E.
    Georgiou, A.
    Angelopoulou, M.
    Kokkori, S.
    Lafioniatis, S.
    Panagiotidis, P.
    Pangalis, G.
    Kyriaki-Manolaraki, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S263 - S264
  • [5] TREATMENT WITH YTTRIUM-90 (90Y)-IBRITUMOMAB TIUXETAN (ZEVALIN®) IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 700 - 700
  • [6] Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma
    Weigert, Oliver
    Illidge, Tim
    Hiddemann, Wolfgang
    Dreyling, Martin
    CANCER, 2006, 107 (04) : 686 - 695
  • [7] Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)
    Morschhauser, F
    Huglo, D
    Martinelli, G
    Paganelli, G
    Zinzani, P
    Hadjiyiannakis, D
    Liberati, A
    Illidge, T
    Milpied, N
    Kalmus, J
    Morel, P
    Reimann, U
    Marcus, R
    ANNALS OF ONCOLOGY, 2005, 16 : 54 - 54
  • [8] Radioimmunotherapy of Recurrent Primary CNS Lymphoma with Yttrium-90 Ibritumomab Tiuxetan
    Pryma, D. A.
    Schwartz, J.
    Nagel, A.
    Zelenetz, A. D.
    Abrey, L. E.
    Humm, J.
    Divgi, C. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S206 - S206
  • [9] Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant
    Arnason, Jon E.
    Luptakova, Katarina
    Rosenblatt, Jacalyn
    Tzachanis, Dimitrios
    Avigan, David
    Zwicker, Jeffrey I.
    Levine, James
    Kim, Michelle
    Parker, J. Anthony
    Grant, Barbara
    Joyce, Robin M.
    ACTA HAEMATOLOGICA, 2015, 133 (04) : 347 - 353
  • [10] Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    McKinney, Matthew S.
    Beaven, Anne W.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 45 - 59
12345